Movement Alert｜REMEGEN Falls 7.65% in Regular Trading, Trading at 71.45 HKD

Market Focus

Oct 02

On October 2, REMEGEN fell 7.65% in regular trading, trading at 71.45 HKD/share, with turnover of 27.75 million HKD.

Within the Biotechnology sector where REMEGEN belongs, the overall sector was broadly weaker. Among individual stocks, BEONE MEDICINES down 6.03%, 3SBIO down 5.43%, SKB BIO down 4.93%, INNOVENT BIO down 4.44%, AKESO down 2.85%.

REMEGEN is a China-based biopharmaceutical company focused on the research, development, production, and commercialization of therapeutic antibody drugs, including antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal and bispecific antibodies. Its key products include Telitacicept and Disitamab Vedotin, applied primarily in autoimmune diseases, oncology, and ophthalmology.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1172648555"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172648555\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172648555?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-02 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172648555","market":"hk","top_or_hot":-1,"title":"Movement Alert｜REMEGEN Falls 7.65% in Regular Trading, Trading at 71.45 HKD","media":"Market Focus","content":"<p><p>On October 2, REMEGEN fell 7.65% in regular trading, trading at 71.45 HKD/share, with turnover of 27.75 million HKD.</p><p>Within the Biotechnology sector where REMEGEN belongs, the overall sector was broadly weaker. Among individual stocks, BEONE MEDICINES down 6.03%, 3SBIO down 5.43%, SKB BIO down 4.93%, INNOVENT BIO down 4.44%, AKESO down 2.85%.</p><p>REMEGEN is a China-based biopharmaceutical company focused on the research, development, production, and commercialization of therapeutic antibody drugs, including antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal and bispecific antibodies. Its key products include Telitacicept and Disitamab Vedotin, applied primarily in autoimmune diseases, oncology, and ophthalmology.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜REMEGEN Falls 7.65% in Regular Trading, Trading at 71.45 HKD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜REMEGEN Falls 7.65% in Regular Trading, Trading at 71.45 HKD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-02 09:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 2, REMEGEN fell 7.65% in regular trading, trading at 71.45 HKD/share, with turnover of 27.75 million HKD.</p><p>Within the Biotechnology sector where REMEGEN belongs, the overall sector was broadly weaker. Among individual stocks, BEONE MEDICINES down 6.03%, 3SBIO down 5.43%, SKB BIO down 4.93%, INNOVENT BIO down 4.44%, AKESO down 2.85%.</p><p>REMEGEN is a China-based biopharmaceutical company focused on the research, development, production, and commercialization of therapeutic antibody drugs, including antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal and bispecific antibodies. Its key products include Telitacicept and Disitamab Vedotin, applied primarily in autoimmune diseases, oncology, and ophthalmology.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1172648555","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172648555","pubTimestamp":1790906011,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 2, REMEGEN fell 7.65% in regular trading, trading at 71.45 HKD/share, with turnover of 27.75 million HKD.Within the Biotechnology sector where REMEGEN belongs, the overall sector was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"走势警报|REMEGEN常规交易跌7.65%，报71.45港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On October 2, REMEGEN fell 7.65% in regular trading, trading at 71.45 HKD/share, with turnover of 27.75 million HKD.Within the Biotechnology sector where REMEGEN belongs, the overall sector was broadly weaker. Among individual stocks, BEONE MEDICINES down 6.03%, 3SBIO down 5.43%, SKB BIO down 4.93%, INNOVENT BIO down 4.44%, AKESO down 2.85%.REMEGEN is a China-based biopharmaceutical company focused on the research, development, production, and commercialization of therapeutic antibody drugs, including antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal and bispecific antibodies. Its key products include Telitacicept and Disitamab Vedotin, applied primarily in autoimmune diseases, oncology, and ophthalmology.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}